Approaches and Challenges in SARS-CoV-2 Vaccine Development

The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are...

Full description

Saved in:
Bibliographic Details
Published inCell Host & Microbe Vol. 28; no. 3; pp. 364 - 370
Main Authors Dagotto, Gabriel, Yu, Jingyou, Barouch, Dan H.
Format Journal Article Web Resource
LanguageEnglish
Published United States Elsevier Inc 09.09.2020
Elsevier BV
Subjects
Animals
Antigens, Viral - chemistry
Antigens, Viral - genetics
Betacoronavirus - genetics
Betacoronavirus - immunology
Coronavirus Infections - epidemiology
Coronavirus Infections - immunology
Coronavirus Infections - prevention & control
COVID-19
COVID-19 Vaccines
Host Microbial Interactions - immunology
Humans
Immunity, Cellular
Immunity, Humoral
Immunity, Innate
Models, Animal
Pandemics - prevention & control
Pneumonia, Viral - epidemiology
Pneumonia, Viral - immunology
Pneumonia, Viral - prevention & control
Primates
SARS-CoV-2
Spike Glycoprotein, Coronavirus - chemistry
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
vaccine
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Viral Vaccines - isolation & purification
COVID-19
SARS-CoV-2
vaccine
Online AccessGet full text

Cover

More Information
Summary:The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection. A vaccine will likely be required to end the SARS-CoV-2 pandemic. In this Perspective, Dagotto, Yu, and Barouch summarize the ongoing preclinical studies on SARS-Cov2 vaccine candidates and discuss standards for antigen selection and immune correlates of protection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
These authors contributed equally to this work
ISSN:1931-3128
1934-6069
DOI:10.1016/j.chom.2020.08.002